BTI 320

Drug Profile

BTI 320

Alternative Names: BTI-320; PAZ-320

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boston Therapeutics
  • Developer Advance Pharmaceutical Co Ltd; Boston Therapeutics
  • Class Antihyperglycaemics; Mannans
  • Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Carbohydrate metabolism inhibitors; Glucose modulators; Hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Efficacy data from a phase II trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 15 Dec 2016 Biomarkers information updated
  • 13 Oct 2016 Advance Pharmaceutical completes a phase II trial in Type-2 diabetes mellitus in Hong Kong prior to October 2016 (9205112; NCT02358668)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top